Coverage, in the open
An evidence rater should be as transparent about its own coverage as it is about the science. Here is everything ClinEvident has graded, organized by indication vertical — and, just as importantly, everything we have screened and concluded does not yet meet the bar to grade. We would rather show you an honest gap than a padded list.
Graded Coverage
What we have graded
Each intervention carries a full six-dimension EGF grade. We build depth within a vertical before adding new ones, so the verticals below are meant to feel complete — not spread thin.
Cardiology
2 gradedInflammation
1 gradedLongevity / Aging
6 gradedMetabolic
2 gradedMusculoskeletal
1 gradedCoverage is growing. New grades are concentrated in cardiometabolic and renal interventions, where the strongest healthspan evidence sits.
Screened — Below the Bar
What we won't grade yet
Under our "no grade without published clinical evidence" rule, popular does not mean gradeable. These interventions were screened and set aside — with the specific reason, and what evidence would move them into the graded set. This list is the honest other half of the product.
| Intervention | Vertical | Why it doesn't grade | Would grade if… |
|---|---|---|---|
| Exosome / "young plasma" infusions | Longevity / Aging |
No human RCT
Marketed at the premium end of the clinic market; human healthspan evidence is absent or pre-clinical. |
A registered, controlled human trial with a defined endpoint. |
| Fisetin | Longevity / Aging |
Animal data only
Strong senolytic signal in mice; human trials are ongoing but published hard-endpoint data is not yet available. |
Published results from the registered human senolytic trials. |
| NAD+ IV therapy | Longevity / Aging |
No human RCT
Widely sold in longevity clinics; there is no RCT demonstrating a healthspan benefit from IV NAD+ infusion. |
Any controlled human trial with a clinical or functional endpoint. |
| NMN (nicotinamide mononucleotide) | Longevity / Aging |
Surrogate endpoints only
Human trials report NAD+ level increases and some functional signals, but no RCT on hard healthspan or mortality endpoints over a meaningful duration. |
A powered human RCT with a functional or clinical endpoint, not just NAD+ levels. |
| NR (nicotinamide riboside) | Longevity / Aging |
Surrogate endpoints only
Raises NAD+ and is well tolerated in humans, but trials have not shown downstream clinical benefit on aging endpoints. |
A trial linking the NAD+ increase to a clinical or functional outcome. |
| Resveratrol | Longevity / Aging |
Underpowered / pilot only
Decades of mechanistic and animal interest, but human trials are small, mixed, and confounded by bioavailability problems. |
A well-powered human trial with a validated endpoint and adequate exposure. |
| Spermidine | Longevity / Aging |
Surrogate endpoints only
Observational dietary associations and small cognitive pilots; no RCT establishing a healthspan effect. |
An RCT with a cognitive or functional endpoint rather than dietary recall. |
| CoQ10 (for healthspan) | Cardiology |
Surrogate endpoints only
Some heart-failure signal exists in its disease context, but as a general healthspan intervention the evidence is biomarker-level, not outcome-level. |
Outcome data in a defined healthspan/preventive population rather than established disease. |
| Methylene blue | Neuro |
Mechanistic only
Popular in biohacking for cognition; human evidence for healthspan use is mechanistic and anecdotal, not from controlled trials. |
A controlled human trial with a cognitive endpoint at the doses being marketed. |
| Colostrum / peptide blends | Immune |
Marketing claims, no trial
Heavily marketed for immune and recovery benefits; the published clinical evidence does not support a gradeable healthspan claim. |
A published RCT with a defined immune or functional endpoint. |
Coverage you can audit
Every grade links to its published evidence. Every gap is documented. Subscribe for full clinical detail across all graded interventions.
See Plans